Southern Research has had long-standing success in cancer research. Five FDA-approved anticancer drugs (lomustine, carmustine, dacarbazine, fludarabine, and clofarabine) and one cytoprotective agent (Ethyol) to reduce toxicities associated with cancer chemotherapy and radiotherapy have been discovered at Southern Research.
The Department of Biochemistry and Molecular Biology has broad research interests in tumor cell biology, mechanism of action of chemotherapeutic drugs, and development of novel therapeutic targets. The Department has strong research programs that are focused on 1) elucidating molecular mechanisms of angiogenesis, apoptosis, and cell cycle regulation, 2) understanding mechanisms of drug resistance, and 3) drug discovery based on purine and pyrimidine metabolism. The Department also has strong research interests in cancer chemoprevention with focused programs in retinoids and nonsteroidal anti-inflammatory drugs to investigate mechanism of action and enhance efficacy, while minimizing toxicity.
Yonghe Li
Zhican Qu
William Parker
Gary A. Piazza
Jaideep Thottassery
Tumor microvessel analysis for panel of subcutaneous xenograft mouse models (256KB, PDF format)
Serotonin: a neurotransmitter as well as a potent angiokine (208KB, PDF format)
Novel small molecules targeting endothelial differentiation (158KB, PDF format)
Serotonin signaling in angiogenesis (126KB, PDF format)
Development of a high content image-based screen to identify small molecules that inhibit growth of human colon cancer cells (927KB, PDF format)
In vivo inhibition of colon tumor cell growth in the HT-29 xenograft model by SRI 21009: a novel sunlindac derivative that potently induces apoptosis but does not inhibit cyclooxygenases (664KB, PDF format)
Sulindac sulfide inhibits growth and induces apoptosis of HT-29 human colon cancer cells through inhibition of PDE5A (254KB, PDF format)
In vitro combination benefits of epidermal growth factor inhibitors and SRI 21009, a novel sulindac derivative that lacks cyclooxygenase inhibitory activity, for human breast cancer (584KB, PDF format)